Search results for "Drug administration"

showing 10 items of 393 documents

Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.

2006

INTRODUCTION: It is assumed that female and male schizophrenic patients respond differentially to acute and chronic treatment with antipsychotics because of pharmacokinetic and pharmacodynamic factors linked to hormonal and constitutional gender differences. However, to date no empirical evidence exists in support of this notion. METHODS: In a naturalistic clinical study, we investigated gender differences in a sample of schizophrenic inpatients with acute exacerbation treated with the atypical antipsychotic amisulpride, a selective dopamine D2/D3 receptor antagonist with proven antipsychotic efficacy. Prescribed amisulpride dose, plasma level, clinical response (CGI), and side effects (UKU…

AdultMalemedicine.medical_specialtySide effectExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPharmacologyDrug Administration ScheduleSex FactorsInternal medicinemedicineHumansPharmacology (medical)AmisulprideAntipsychoticmedicine.diagnostic_testGeneral MedicineDrug ToleranceHospitalizationPsychiatry and Mental healthTherapeutic drug monitoringPharmacodynamicsSchizophreniaFemaleAmisulprideDrug MonitoringSulpiridePsychologySulpiridemedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controll…

2009

Objective To assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles. Design Single-center, randomized, single-blind, placebo-controlled trial. Setting University-affiliated infertility clinic, between February 2005 and December 2007. Patient(s) Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication. Intervention(s) Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n = 172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time. Main Outcome Measure(s) Pregnancy rate was the primary outcom…

AdultMalemedicine.medical_specialtyTime FactorsPregnancy Ratemedicine.medical_treatmentLuteal phaseDrug Administration Schedulelaw.inventionMiscarriageGonadotropin-Releasing HormonePlacebosRandomized controlled triallawPregnancyMedicineHumansSingle-Blind MethodEmbryo ImplantationInsemination ArtificialGynecologyPregnancyTriptorelin Pamoatebusiness.industryObstetricsArtificial inseminationUterusPregnancy OutcomeObstetrics and GynecologyFertility Agents Femalemedicine.diseaseTriptorelinPregnancy rateReproductive MedicineGestationFemalebusinessAlgorithmsmedicine.drugFertility and sterility
researchProduct

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

2012

A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].

AdultMalemedicine.medical_specialtyTime FactorsPyridonesHeart VentriclesThalassemiaDeferoxamineIron Chelating AgentsModels BiologicalDrug Administration Schedulechemistry.chemical_compoundInternal medicineHumansMedicineLeft ventricular ejectionDeferiproneIn patientRetrospective StudiesUltrasonographyEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeHematologymedicine.diseasehumanitieschemistryCardiologyDrug Therapy CombinationFemaleThalassemia major Left ventricular ejection fraction Deferiprone sequential deferiprone-deferoxamine Echocardiography ChelationbusinessDeferiproneAmerican Journal of Hematology
researchProduct

Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels

2002

In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. After completing 6 weeks of medication with either amisulpride or flupenthixol, the patients entered a long-term maintenance treatment with amisulpride 200–600 mg/day or flupenthixol 5–15 mg/day for a maximum of 12 months with a subsequent drug-free follow-up until month 15. Eighteen initially included patients were still participating in the study at month 6. In the flupenthixol group, only 1 patient treated reached month 12, and none of t…

AdultMalemedicine.medical_specialtyTime FactorsThyrotropin-releasing hormoneFlupenthixolDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansAmisulprideBenzamideThyrotropin-Releasing HormoneBiological PsychiatryMiddle AgedProlactinProlactinFlupentixolFlupenthixolPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologychemistrySchizophreniaFemaleAmisulprideSulpiridePsychologyAntipsychotic Agentsmedicine.drugHormoneNeuropsychobiology
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct

Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.

2011

Abstract The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinHemorrhageDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRecurrenceRisk Factorsdeep vein thrombosis (DVT)Residual vein thrombosismedicineHumansProspective Studiesdeep vein thrombosis (DVT); vitamin K antagonist (VKA) therapy; Residual vein thrombosisProspective cohort studyAgedUltrasonographyVenous Thrombosisbusiness.industryAcenocoumarolAnticoagulantsHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryClinical trialVein thrombosisvitamin K antagonist (VKA) therapymedicine.anatomical_structureLower ExtremityRelative riskFemaleWarfarinbusiness
researchProduct

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

2011

SUMMARYOptimal antiretroviral strategies for HIV-infected patients still need to be established. To this end a decision tree including different antiretroviral strategies that could be adopted for HIV-infected patients was built. A 10-year follow-up was simulated by using transitional probabilities estimated from a large cohort using a time-homogeneous Markov model. The desired outcome was for patients to maintain a CD4 cell count of >500 cells/mm3without experiencing AIDS or death. For patients with a baseline HIV viral load ⩾5 log10copies/ml, boosted protease inhibitor-based immediate highly active antiretroviral therapy (HAART) allowed them to spend 12% more time with CD4 ⩾500/mm3than…

AdultMalemedicine.medical_specialty[ INFO ] Computer Science [cs]EpidemiologyAnti-HIV AgentsDecision treeHIV InfectionsDrug Administration ScheduleCohort Studies03 medical and health sciences0302 clinical medicineLife ExpectancyAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActiveHiv infected patientsMedicineHumansProtease inhibitor (pharmacology)In patient[INFO]Computer Science [cs]Computer Simulation030212 general & internal medicineCd4 cell countComputingMilieux_MISCELLANEOUS0303 health sciences030306 microbiologybusiness.industryDecision TreesMiddle AgedViral Loadmedicine.diseaseAntiretroviral therapyMarkov Chains3. Good healthCD4 Lymphocyte CountInfectious DiseasesTreatment OutcomeImmunologyDisease ProgressionFemalebusinessViral loadFollow-Up StudiesEpidemiology and infection
researchProduct

Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation base…

2008

Abstract Residual vein thrombosis (RVT) indicates a prothrombotic state and is useful for evaluating the optimal duration of oral anticoagulant treatment (OAT). Patients with a first episode of deep vein thrombosis, treated with OAT for 3 months, were managed according to RVT findings. Those with RVT were randomized to either stop or continue anticoagulants for 9 additional months, whereas in those without RVT, OAT was stopped. Outcomes were recurrent venous thromboembolism and/or major bleeding. Residual thrombosis was detected in 180 (69.8%) of 258 patients; recurrent events occurred in 27.2% of those who discontinued (25/92; 15.2% person-years) and 19.3% of those who continued OAT (17/88…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep veinImmunologyHemorrhageBiochemistryDrug Administration ScheduleSettore MED/15 - Malattie Del SangueDeep vein thrombosioral anticoagulantSecondary PreventionmedicineHumansAgedUltrasonographyVenous ThrombosisFirst episoderesidual vein thrombosisVascular diseasebusiness.industryAnticoagulantHazard ratioAnticoagulantsCell BiologyHematologyMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisConfidence intervalSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemalebusinessBlood
researchProduct

Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.

2006

Although cyclosporin is effective in immunosuppression following organ transplantation and in the treatment of psoriasis, its use is limited by its side-effects, notably impaired renal function and hypertension. As SDZ IMM 125, a new derivative of the cyclosporin family, showed considerable immunosuppressive activity in experimental studies, with less effect on renal function, it was considered a potential successor to cyclosporin for both indications. In this multicentre, double-blind, placebo-controlled study, the efficacy and tolerability of 40, 100, 200 and 400 mg SDZ IMM 125 daily were studied in 59 patients with psoriasis. Patients were followed for a period of 5 weeks (4 weeks treatm…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRenal functionCyclosporinsDermatologyPharmacologyGastroenterologyDrug Administration ScheduleDouble-Blind MethodInternal medicinePsoriasismedicineHumansPsoriasisAdverse effectBody surface areaChemotherapyDose-Response Relationship Drugbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseTolerabilityToxicityFemalebusinessImmunosuppressive AgentsFollow-Up StudiesThe British journal of dermatology
researchProduct